{"id":6660,"date":"2024-11-21T14:50:13","date_gmt":"2024-11-21T13:50:13","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6660"},"modified":"2025-04-28T21:50:00","modified_gmt":"2025-04-28T19:50:00","slug":"tislelizumab-plus-chemotherapy-as-first-line-treatment-of-locally-advanced-or-metastatic-nonsquamous-non-small-cell-lung-cancer-final-analysis-of-rationale-304-a-randomized-phase-iii-trial","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/tislelizumab-plus-chemotherapy-as-first-line-treatment-of-locally-advanced-or-metastatic-nonsquamous-non-small-cell-lung-cancer-final-analysis-of-rationale-304-a-randomized-phase-iii-trial\/","title":{"rendered":"Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial)"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6660","publication","type-publication","status-publish","hentry","disease_state-non-small-cell-lung-cancer","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6660"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}